Abiopharma

🔍 Boyle Robert E (Executive)

Company: PRUDENTIAL FINANCIAL INC (PRU)

Report Date: 2026-08-31

Detailed Transactions and Holdings:

• Acquired 353 shares of Common Stock (Direct)
  Date: 2026-08-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,087.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 115 shares of Common Stock at $117.6 per share (Direct)
  Date: 2026-08-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 5,972.00 | transaction_form_type: 4 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-31 | Code: H | nature_of_ownership: By 401(k) | shares_owned_after: 962.00 | Footnotes: F4
• Sold 353 shares of 8/10/2023 Restricted Stock Units (Derivative)
  Date: 2026-08-31 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F5, F6, F6

Footnotes:

• F1: Represents the vesting of previously awarded restricted stock units.
• F2: The amount of securities beneficially owned by Mr. Boyle was incorrectly stated on the Form 4 filed on 2/11/26 in Column 5 thereof due to a calculation error, and this error was also reflected in Mr. Boyle's Form 4 filed on 3/03/26 in Column 5 thereof. The error has been corrected in this report in Column 5.
• F3: Represents shares withheld for the payment of taxes.
• F4: Amount reported has been adjusted to include 27 shares of Issuer common stock acquired by the reporting person under The Prudential Employee Savings Plan between December 31, 2025, and June 30, 2026, based on a plan statement dated June 30, 2026. The acquisition of such shares was exempt from Section 16 pursuant to Rules 16b-3(c) and 16a-3(f)(1)(i)(B).
• F5: The Restricted Stock Units convert to common stock on a 1 to 1 basis.
• F6: The Restricted Stock Units will vest 1/3 per year beginning the last day of August 2024.